PECAM1 and prostate cancer: Anti-CD31 immunohistochemical staining showed that (–)-gossypol plus radiation significantly inhibited tumor angiogenesis, thus indicating that it could radiosensitize prostate cancer in vitro and in vivo without exacerbating toxicity [74].